Kazia Therapeutics Files 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Dec 11, 2024 · CIK: 1075880
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed a 6-K, confirming 20-F annual reports. Standard regulatory update.
AI Summary
Kazia Therapeutics Limited filed a Form 6-K on December 11, 2024. The filing is a report of a foreign private issuer and indicates that Kazia Therapeutics Limited files annual reports under Form 20-F. The company's principal executive office is located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Why It Matters
This filing provides standard regulatory information for Kazia Therapeutics Limited as a foreign private issuer, confirming their reporting structure with the SEC.
Risk Assessment
Risk Level: low — This filing is a routine regulatory report and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000 (location) — Principal executive office address
- 000-29962 (other) — SEC File Number
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Which form does Kazia Therapeutics Limited use for its annual reports?
Kazia Therapeutics Limited files annual reports under cover of Form 20-F.
What is the company's principal executive office address?
The principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
What is the SEC file number for Kazia Therapeutics Limited?
The SEC file number is 000-29962.
When was the company formerly known as Novogen Ltd?
The company was formerly known as Novogen Ltd, with a date of name change on December 28, 1998.
Filing Stats: 301 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2024-12-11 08:58:43
Filing Documents
- d904031d6k.htm (6-K) — 10KB
- d904031dex991.htm (EX-99.1) — 14KB
- g904031g1211020047388.jpg (GRAPHIC) — 3KB
- 0001193125-24-274916.txt ( ) — 29KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On December 11, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled, Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Companys registration statements on Form F-3 (File No. 333-276091 and 333-281937). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated December 11, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 11 December 2024